PHAXIAM Therapeutics (PHXM) Competitors $3.10 0.00 (0.00%) (As of 12/24/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrends PHXM vs. ICCC, CVM, SCYX, ACHL, ATNM, JATT, CLNN, BRNS, LTRN, and CALCShould you be buying PHAXIAM Therapeutics stock or one of its competitors? The main competitors of PHAXIAM Therapeutics include ImmuCell (ICCC), CEL-SCI (CVM), SCYNEXIS (SCYX), Achilles Therapeutics (ACHL), Actinium Pharmaceuticals (ATNM), JATT Acquisition (JATT), Clene (CLNN), Barinthus Biotherapeutics (BRNS), Lantern Pharma (LTRN), and CalciMedica (CALC). These companies are all part of the "pharmaceutical products" industry. PHAXIAM Therapeutics vs. ImmuCell CEL-SCI SCYNEXIS Achilles Therapeutics Actinium Pharmaceuticals JATT Acquisition Clene Barinthus Biotherapeutics Lantern Pharma CalciMedica PHAXIAM Therapeutics (NASDAQ:PHXM) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk, community ranking and media sentiment. Is PHXM or ICCC more profitable? PHAXIAM Therapeutics has a net margin of 0.00% compared to ImmuCell's net margin of -15.99%. PHAXIAM Therapeutics' return on equity of 0.00% beat ImmuCell's return on equity.Company Net Margins Return on Equity Return on Assets PHAXIAM TherapeuticsN/A N/A N/A ImmuCell -15.99%-15.32%-8.81% Do insiders and institutionals have more ownership in PHXM or ICCC? 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Comparatively, 6.6% of ImmuCell shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, PHXM or ICCC? PHAXIAM Therapeutics has a beta of 2.35, meaning that its stock price is 135% more volatile than the S&P 500. Comparatively, ImmuCell has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Does the MarketBeat Community believe in PHXM or ICCC? ImmuCell received 121 more outperform votes than PHAXIAM Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformPHAXIAM TherapeuticsN/AN/AImmuCellOutperform Votes12173.33% Underperform Votes4426.67% Which has preferable valuation and earnings, PHXM or ICCC? PHAXIAM Therapeutics has higher revenue and earnings than ImmuCell. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPHAXIAM Therapeutics$32.66M0.32-$240KN/AN/AImmuCell$23.84M1.72-$5.78M-$0.50-9.22 Does the media refer more to PHXM or ICCC? In the previous week, PHAXIAM Therapeutics' average media sentiment score of 0.00 equaled ImmuCell'saverage media sentiment score. Company Overall Sentiment PHAXIAM Therapeutics Neutral ImmuCell Neutral SummaryPHAXIAM Therapeutics beats ImmuCell on 6 of the 10 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get PHAXIAM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHXM vs. The Competition Export to ExcelMetricPHAXIAM TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.58M$170.83M$5.22B$9.25BDividend YieldN/A3.64%5.12%4.29%P/E RatioN/A115.5687.5117.27Price / Sales0.3219,393.491,166.59119.77Price / CashN/A13.0143.2337.83Price / Book0.398.754.834.93Net Income-$240,000.00-$20.89M$120.46M$225.34M7 Day PerformanceN/A1.43%2.85%4.14%1 Month PerformanceN/A244.61%19.70%1.16%1 Year Performance-31.26%150.48%30.57%16.98% PHAXIAM Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049ICCCImmuCellN/A$4.69-4.7%N/A-1.5%$41.80M$23.84M-9.3875Positive NewsGap DownCVMCEL-SCIN/A$0.65-5.8%N/A-74.5%$41.48MN/A-1.1943News CoverageSCYXSCYNEXIS0.8545 of 5 stars$1.08-5.3%N/A-46.8%$40.99M$8.57M-1.4660ACHLAchilles Therapeutics3.2319 of 5 stars$0.99-0.3%$4.00+305.3%+39.0%$40.56MN/A-0.60250News CoverageATNMActinium Pharmaceuticals1.2683 of 5 stars$1.27+3.3%$7.40+482.7%N/A$39.62M$81,000.00-0.8849JATTJATT AcquisitionN/A$2.28+3.6%N/A-56.7%$39.33MN/A0.003News CoverageHigh Trading VolumeCLNNClene3.8328 of 5 stars$4.70-5.1%$55.25+1,075.5%-13.8%$39.29M$650,000.00-0.94100BRNSBarinthus Biotherapeutics1.5795 of 5 stars$0.97+6.8%$5.83+498.8%-66.5%$39.19M$800,000.00-0.61107Gap UpLTRNLantern Pharma0.9313 of 5 stars$3.56+3.5%N/A-23.7%$38.40MN/A-1.9420CALCCalciMedica2.8546 of 5 stars$2.81+2.9%$19.33+588.0%-6.2%$37.88MN/A-2.5330Positive News Related Companies and Tools Related Companies ImmuCell Competitors CEL-SCI Competitors SCYNEXIS Competitors Achilles Therapeutics Competitors Actinium Pharmaceuticals Competitors JATT Acquisition Competitors Clene Competitors Barinthus Biotherapeutics Competitors Lantern Pharma Competitors CalciMedica Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PHXM) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PHAXIAM Therapeutics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share PHAXIAM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHXM Stock Alerts